SciSparc Enhances Autism Treatment Options
SciSparc Ltd. (Nasdaq: SPRC), a pharmaceutical company specializing in advanced treatments for central nervous system disorders, recently made a significant announcement regarding its clinical trial for SCI-210. This trial focuses on children with autism spectrum disorder (ASD) and is approved by the Israeli Medical Cannabis Agency.
Renewal of Clinical Trial Approval
As part of its commitment to pioneering medical advancements, SciSparc successfully renewed its approval from the Israeli Medical Cannabis Agency, allowing it to continue its innovative clinical trial for SCI-210. This drug combines cannabidiol (CBD) with CannAmide™, reflecting the company’s cutting-edge approach to treating ASD. The renewal reaffirms the company's adherence to regulatory requirements, a crucial aspect of conducting clinical research.
Details of the Clinical Trial
The clinical trial is unique in that it is a double-blind, randomized, and placebo-controlled study involving a select group of 60 children aged 5 to 18 diagnosed with ASD. Conducted at Soroka University Medical Center, the trial aims to assess both the efficacy and safety of SCI-210 compared to traditional CBD treatments. Over a 20-week program, participants will undergo treatment with a clear focus on managing symptoms associated with autism and identifying effective therapeutic doses.
Evaluating ADHD Outcomes
The primary efficacy metrics designed for this trial include tools like the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire and the Clinical Global Impressions-Improvement (CGI-I) scale. These metrics will play a crucial role in determining the success and effectiveness of SCI-210 in addressing the challenges faced by children with ASD. The trial is designed with guidance from the National Autism Research Center, increasing its credibility and potential impact.
Commitment to Innovation
With plans to commercialize SCI-210 first in the Israeli market, SciSparc is eager to expand its reach internationally, contingent on receiving necessary regulatory approvals. The company is dedicated to addressing unmet needs in autism treatment, emphasizing a strong commitment to improving the quality of life for children and families affected by this condition.
Company Overview and Future Directions
SciSparc is not only focused on developing SCI-210 but also actively engaged in creating a robust portfolio of cannabinoid-based therapies. This includes programs aimed at treating conditions like Tourette Syndrome and Alzheimer's disease. The company has built a reputation for excellence in the pharmaceutical landscape, backed by a seasoned team of executives and scientists. Furthermore, SciSparc holds a controlling interest in a subsidiary that offers hemp seed oil products through online marketplaces.
Frequently Asked Questions
What is the purpose of the SCI-210 clinical trial?
The SCI-210 trial aims to evaluate the efficacy and safety of a novel treatment for children with autism spectrum disorder.
What does the approval from the Israeli Medical Cannabis Agency entail?
The approval allows SciSparc to proceed with its clinical trial, ensuring it meets all regulatory requirements for patient safety and research integrity.
How many participants are involved in the trial?
There are 60 children participating in the double-blind, randomized study.
How long will the treatment last for participants in the trial?
The treatment program for participants lasts for 20 weeks.
What are the main goals of the clinical trial?
The trial aims to assess symptom management and identify effective therapeutic doses through various efficacy metrics.